FDA panel recommends approval of Edwards transcatheter heart valve for certain inoperable patients.
If the valve gains approval, the Edwards device would be the first co-called transcatheter valve sold in a US market estimated to reach $1.3 billion by 2014, according to a report from Bloomberg Industries. The valve has been available in Europe since 2007.
About 300,000 people in the US suffer from aortic stenosis, according to Edwards. Two-thirds undergo standard chest-cracking surgery to replace the valve, while the risk of surgery may be too high for the rest.
For more information go to: http://www.edwards.com
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 1, 2011|
|Previous Article:||Mesoblast receives FDA clearance for Phase 3 bone marrow transplant using adult stem cells.|
|Next Article:||BD Diagnostics, Biodiversity to collaborate in developing diagnostic menu for patients to monitor infections in immunocompromised patients.|